28 results on '"Vassal G."'
Search Results
2. Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children.
- Author
-
Cheng, K., Mahler, F.M., Lutsar, I., Escalera, B.N., Breitenstein, S., Vassal, G., Claverol, J., Palacio, N.N., Portman, R., Pope, G., Bakker, Martijn, Geest, T. van der, Turner, Mark A.A., Wildt, S.N. de, Cheng, K., Mahler, F.M., Lutsar, I., Escalera, B.N., Breitenstein, S., Vassal, G., Claverol, J., Palacio, N.N., Portman, R., Pope, G., Bakker, Martijn, Geest, T. van der, Turner, Mark A.A., and Wildt, S.N. de
- Abstract
Item does not contain fulltext, Many medicines are used "off-label" in children outside the terms of the license. Feasible pediatric clinical trials are a challenge to design. Conect4children (c4c) is an Innovative Medicines Initiative project to set up a pan-European pediatric clinical trial network aiming to facilitate the development of new medicines for children. To optimize pediatric trial development by promoting innovative trial design, c4c set up a European multidisciplinary advice service, including the voice of young patients and families, tailored to industry and academia. A network of experts was established to provide multidisciplinary advice to trial sponsors. Experts were selected to join clinical and innovative methodology expert groups. A patient and public involvement (PPI) database, to include the expert opinion of patients and parents/carers was formed. A stepwise process was developed: (1) sponsors contact c4c, (2) scoping interview takes place, (3) ad hoc advice group formed, (5) advice meeting held, and (6) advice report provided. Feedback on the process was collected. Twenty-four clinical and innovative methodology expert groups (>400 experts) and a PPI database of 135 registrants were established. As of September 30, 2022, 36 advice requests were received, with 25 requests completed. Clinical and methodology experts and PPI representatives participated in several advice requests. Sponsors appreciated the advice quality and the multidisciplinary experts from different countries, including experts not known before. Experts and PPI participants were generally satisfied with the process. The c4c project has shown successful proof of concept for a service that presents a new framework to plan innovative and feasible pediatric trials.
- Published
- 2023
3. Intercontinental collaboration in clinical trials for children and adolescents with cancer—A systematic review by ACCELERATE
- Author
-
de Rojas, T, Pearson, A, Scobie, N, Knox, L, Wariabharaj, D, Kearns, P, Vassal, G, Reaman, G, Alonzo, T, Biondi, A, Brodeur-Robb, K, Fouladi, M, Gross, T, Hunger, S, Mccowage, G, Pappo, A, Schrappe, M, Grazia Valsecchi, M, Weigel, B, Wejbora, P, Whitlock, J, Zwaan, M, Buenger, V, Ludwinski, D, Barry, E, Neville, K, Sharma, A, Karres, D, de Rojas T., Pearson A. J., Scobie N., Knox L., Wariabharaj D., Kearns P., Vassal G., Reaman G., Alonzo T., Biondi A., Brodeur-Robb K., Fouladi M., Gross T., Hunger S., McCowage G., Pappo A., Schrappe M., Grazia Valsecchi M., Weigel B., Wejbora P., Whitlock J., Zwaan M., Buenger V., Ludwinski D., Barry E., Neville K., Sharma A., Karres D., de Rojas, T, Pearson, A, Scobie, N, Knox, L, Wariabharaj, D, Kearns, P, Vassal, G, Reaman, G, Alonzo, T, Biondi, A, Brodeur-Robb, K, Fouladi, M, Gross, T, Hunger, S, Mccowage, G, Pappo, A, Schrappe, M, Grazia Valsecchi, M, Weigel, B, Wejbora, P, Whitlock, J, Zwaan, M, Buenger, V, Ludwinski, D, Barry, E, Neville, K, Sharma, A, Karres, D, de Rojas T., Pearson A. J., Scobie N., Knox L., Wariabharaj D., Kearns P., Vassal G., Reaman G., Alonzo T., Biondi A., Brodeur-Robb K., Fouladi M., Gross T., Hunger S., McCowage G., Pappo A., Schrappe M., Grazia Valsecchi M., Weigel B., Wejbora P., Whitlock J., Zwaan M., Buenger V., Ludwinski D., Barry E., Neville K., Sharma A., and Karres D.
- Abstract
Background: Since pediatric cancer drug development is a global enterprise, we sought to provide an overview of the landscape of intercontinental clinical trials in pediatric oncology opened over the last decade. Methods: ClinicalTrials.gov was systematically searched to identify all clinical therapeutic trials which opened between 2010 and 2020 and recruited pediatric patients (<18 years) with cancer. Results: Over the last 10 years, 295 (8.7%) of 3383 therapeutic pediatric cancer trials were international and 182 (5.4%) were intercontinental. Most intercontinental trials were phase-1 or 2, with 25% late-phase, 65% were sponsored by industry, and North America was involved in 92%. Industry-sponsored proportionally more phase-1 trials than academia (41% vs. 25%); conversely, academia sponsored more phase-2 and late-phase trials (39% and 31% vs. 36% and 21%, respectively) (p = 0.020). North America–Europe collaboration was predominantly industry sponsored as opposed to North America–Oceania and Europe–Oceania collaboration, more frequently academic (p < 0.0001). Most late-phase trials (18/20, 90%) focusing on pediatric malignancies were conducted by academic sponsors and 10 of these were conducted by Children's Oncology Group (COG)/National Cancer Institute in the United States and Oceania. There was no significant increase over time of intercontinental trials and a trend for a reduction in academic trials. Conclusions: Despite the relative rarity of childhood malignancies, especially within molecular subtypes, only 5.4% of pediatric cancer trials were intercontinental. The number of intercontinental trials remains small, with no significant increase over the last decade. The ACCELERATE International Collaboration Working Group aims to identify existing hurdles and propose solutions to improve intercontinental collaboration in clinical research for the benefit of children and adolescents with cancer.
- Published
- 2021
4. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
- Author
-
Prokoph, N, Probst, N, Lee, L, Monahan, J, Matthews, J, Liang, H, Bahnsen, K, Montes-Mojarro, I, Karaca-Atabay, E, Sharma, G, Malik, V, Larose, H, Forde, S, Ducray, S, Lobello, C, Wang, Q, Luan, S, Pospisilova, S, Gambacorti Passerini, C, Burke, G, Pervez, S, Attarbaschi, A, Janikova, A, Pacquement, H, Landman-Parker, J, Lambilliotte, A, Schleiermacher, G, Klapper, W, Jauch, R, Woessmann, W, Vassal, G, Kenner, L, Merkel, O, Mologni, L, Chiarle, R, Brugieres, L, Geoerger, B, Barbieri, I, Turner, S, Prokoph N., Probst N. A., Lee L. C., Monahan J. M., Matthews J. D., Liang H. -C., Bahnsen K., Montes-Mojarro I. A., Karaca-Atabay E., Sharma G. G., Malik V., Larose H., Forde S. D., Ducray S. P., Lobello C., Wang Q., Luan S. -L., Pospisilova S., Gambacorti Passerini C., Burke G. A. A., Pervez S., Attarbaschi A., Janikova A., Pacquement H., Landman-Parker J., Lambilliotte A., Schleiermacher G., Klapper W., Jauch R., Woessmann W., Vassal G., Kenner L., Merkel O., Mologni L., Chiarle R., Brugieres L., Geoerger B., Barbieri I., Turner S. D., Prokoph, N, Probst, N, Lee, L, Monahan, J, Matthews, J, Liang, H, Bahnsen, K, Montes-Mojarro, I, Karaca-Atabay, E, Sharma, G, Malik, V, Larose, H, Forde, S, Ducray, S, Lobello, C, Wang, Q, Luan, S, Pospisilova, S, Gambacorti Passerini, C, Burke, G, Pervez, S, Attarbaschi, A, Janikova, A, Pacquement, H, Landman-Parker, J, Lambilliotte, A, Schleiermacher, G, Klapper, W, Jauch, R, Woessmann, W, Vassal, G, Kenner, L, Merkel, O, Mologni, L, Chiarle, R, Brugieres, L, Geoerger, B, Barbieri, I, Turner, S, Prokoph N., Probst N. A., Lee L. C., Monahan J. M., Matthews J. D., Liang H. -C., Bahnsen K., Montes-Mojarro I. A., Karaca-Atabay E., Sharma G. G., Malik V., Larose H., Forde S. D., Ducray S. P., Lobello C., Wang Q., Luan S. -L., Pospisilova S., Gambacorti Passerini C., Burke G. A. A., Pervez S., Attarbaschi A., Janikova A., Pacquement H., Landman-Parker J., Lambilliotte A., Schleiermacher G., Klapper W., Jauch R., Woessmann W., Vassal G., Kenner L., Merkel O., Mologni L., Chiarle R., Brugieres L., Geoerger B., Barbieri I., and Turner S. D.
- Abstract
Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by nucleophosmin 1 (NPM1)-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54% to 90% in clinical trials; however, a subset of patients progressed within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) activation and knockout screens in ALCL cell lines, combined with RNA sequencing data derived from ALK inhibitor-relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of interleukin 10 receptor subunit alpha (IL10RA). Elevated IL10RA expression rewires the STAT3 signaling pathway, bypassing otherwise critical phosphorylation by NPM1-ALK. IL-10RA expression does not correlate with response to standard chemotherapy in pediatric patients, suggesting that a combination of crizotinib and chemotherapy could prevent ALK inhibitor resistance-specific relapse.
- Published
- 2020
5. A European paediatric cancer mission: aspiration or reality?
- Author
-
Kearns, P, Vassal, G, Ladenstein, R, Schrappe, M, Biondi, A, Blanc, P, Eggert, A, Kienesberger, A, Kozhaeva, O, Pieters, R, Schmiegelow, K, Kearns P. R., Vassal G., Ladenstein R., Schrappe M., Biondi A., Blanc P., Eggert A., Kienesberger A., Kozhaeva O., Pieters R., Schmiegelow K., Kearns, P, Vassal, G, Ladenstein, R, Schrappe, M, Biondi, A, Blanc, P, Eggert, A, Kienesberger, A, Kozhaeva, O, Pieters, R, Schmiegelow, K, Kearns P. R., Vassal G., Ladenstein R., Schrappe M., Biondi A., Blanc P., Eggert A., Kienesberger A., Kozhaeva O., Pieters R., and Schmiegelow K.
- Published
- 2019
6. Access to essential anticancer medicines for children and adolescents in Europe
- Author
-
Universitat Politècnica de València. Departamento de Mecánica de los Medios Continuos y Teoría de Estructuras - Departament de Mecànica dels Medis Continus i Teoria d'Estructures, European Commission, Vassal, G., Kozhaeva, O., Griskjane, S., Arnold, F., Nysom, K., Basset-Salom, Luisa, Kameric, L., Kienesberger, A., Kamal, S., Cherny, N., Bricalli, G., Latino, N., Kearns, P., Universitat Politècnica de València. Departamento de Mecánica de los Medios Continuos y Teoría de Estructuras - Departament de Mecànica dels Medis Continus i Teoria d'Estructures, European Commission, Vassal, G., Kozhaeva, O., Griskjane, S., Arnold, F., Nysom, K., Basset-Salom, Luisa, Kameric, L., Kienesberger, A., Kamal, S., Cherny, N., Bricalli, G., Latino, N., and Kearns, P.
- Abstract
[EN] Background: Essential anticancer medicines are an indispensable component of multidisciplinary treatment of paediatric malignancies. A European Society for Medical Oncology (ESMO) study reported inequalities in the availability of anticancer medicines for adult solid tumours and provided a model for the present survey. The aim of this survey was to assess the accessibility of essential medicines used in paediatric cancer patients aged 0 to 18 years across Europe from 2016 to 2018. Methods: A list of medicines was drawn with input from the European Society for Paediatric Oncology (SIOP Europe) Clinical Research Council referring to the World Health Organization Model List of Essential Medicines for Children (WHO EMLc) 2017. A survey was sent to nominated national clinician and pharmacist rapporteurs and parent associations in up to 37 countries; answers were obtained from 34 countries. Results: The full survey list contained 68 medicines, including 24 on the WHO EMLc 2017. Health professionals reported that 35% of all medicines were prescribed off-label in at least one country and that 44% were always available in >90% of countries. Only 63% of the EMLc 2017 medicines were reported as always available. The main determinant of unavailability was shortages, reported for 72% of medicines in at least one country. Out-of-pocket costs were reported in eight countries. Twenty-seven percent of orally administered medicines were never available in childfriendly formulations. Parents detailed individual efforts and challenges of facilitating ingestion of oral medicines as prescribed. Inequalities in access to pain control during procedures were reported by parents across Europe. Conclusions: Children and adolescents with cancer in Europe experience lack of access to essential medicines. Urgent actions are needed to address shortages, financial accessibility, availability of safe age-appropriate oral formulations, and pain management across Europe.
- Published
- 2021
7. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
- Author
-
Amoroso, L., Castel, V., Bisogno, G., Casanova, M., Marquez-Vega, C., Chisholm, J. C., Doz, F., Moreno, L., Ruggiero, Antonio, Gerber, N. U., Fagioli, F., Hingorani, P., Melcon, S. G., Slepetis, R., Chen, N., le Bruchec, Y., Simcock, M., Vassal, G., Ruggiero A. (ORCID:0000-0002-6052-3511), Amoroso, L., Castel, V., Bisogno, G., Casanova, M., Marquez-Vega, C., Chisholm, J. C., Doz, F., Moreno, L., Ruggiero, Antonio, Gerber, N. U., Fagioli, F., Hingorani, P., Melcon, S. G., Slepetis, R., Chen, N., le Bruchec, Y., Simcock, M., Vassal, G., and Ruggiero A. (ORCID:0000-0002-6052-3511)
- Abstract
Background: The phase I component of a phase I/II study defined the recommended phase II dose and established the tolerability of nab-paclitaxel monotherapy in paediatric patients with recurrent or refractory solid tumours. The activity and safety of nab-paclitaxel monotherapy was further investigated in this phase II study. Patients and methods: Paediatric patients with recurrent or refractory Ewing sarcoma, neuroblastoma or rhabdomyosarcoma received 240 mg/m2 of nab-paclitaxel on days 1, 8 and 15 of each 28-day cycle. The primary end-point was the overall response rate (ORR; complete response [CR] + partial response [PR]). Secondary end-points included duration of response, disease control rate (DCR; CR + PR + stable disease [SD]), progression-free survival, 1-year overall survival, safety and pharmacokinetics. Results: Forty-two patients were enrolled, 14 each with Ewing sarcoma, neuroblastoma and rhabdomyosarcoma. The ORRs were 0%, 0% and 7.1% (1 confirmed PR), respectively. The DCRs were 30.8% (4 SD), 7.1% (1 SD) and 7.1% (1 confirmed PR and 0 SD) in the Ewing sarcoma, neuroblastoma and rhabdomyosarcoma groups, respectively. The median progression-free survival was 13.0, 7.4 and 5.1 weeks, respectively, and the 1-year overall survival rates were 48%, 25% and 15%, respectively. The most common grade III/4IVadverse events were haematologic (neutropenia [50%] and anaemia [48%]), and grade III/IV peripheral neuropathy occurred in 2 patients (14%) in the rhabdomyosarcoma group. Pharmacokinetics analyses revealed that paclitaxel tissue distribution was both rapid and extensive. Conclusions: In this phase II study, limited activity was observed; however, the safety of nab-paclitaxel in paediatric patients was confirmed. Trial registration: NCT01962103 and EudraCT 2013-000144-26.
- Published
- 2020
8. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium
- Author
-
Rubio-San-Simon, A., Andre, N., Cefalo, M. G., Aerts, I., Castaneda, A., Benezech, S., Makin, G., van Eijkelenburg, N., Nysom, K., Marshall, L., Gambart, M., Hladun, R., Rossig, C., Bergamaschi, L., Fagioli, F., Carpenter, B., Ducassou, S., Owens, C., Ora, I., Ribelles, A. J., De Wilde, B., Guerra-Garcia, P., Strullu, M., Rizzari, C., Ek, T., Hettmer, S., Gerber, N. U., Rawlings, C., Diezi, M., Palmu, S., Ruggiero, Antonio, Verdu, J., de Rojas, T., Vassal, G., Geoerger, B., Moreno, L., Bautista, F., Ruggiero A. (ORCID:0000-0002-6052-3511), Rubio-San-Simon, A., Andre, N., Cefalo, M. G., Aerts, I., Castaneda, A., Benezech, S., Makin, G., van Eijkelenburg, N., Nysom, K., Marshall, L., Gambart, M., Hladun, R., Rossig, C., Bergamaschi, L., Fagioli, F., Carpenter, B., Ducassou, S., Owens, C., Ora, I., Ribelles, A. J., De Wilde, B., Guerra-Garcia, P., Strullu, M., Rizzari, C., Ek, T., Hettmer, S., Gerber, N. U., Rawlings, C., Diezi, M., Palmu, S., Ruggiero, Antonio, Verdu, J., de Rojas, T., Vassal, G., Geoerger, B., Moreno, L., Bautista, F., and Ruggiero A. (ORCID:0000-0002-6052-3511)
- Abstract
Introduction: Data regarding real-world impact on cancer clinical research during COVID-19 are scarce. We analysed the impact of the COVID-19 pandemic on the conduct of paediatric cancer phase I–II trials in Europe through the experience of the Innovative Therapies for Children with Cancer (ITCC). Methods: A survey was sent to all ITCC-accredited early-phase clinical trial hospitals including questions about impact on staff activities, recruitment, patient care, supply of investigational products and legal aspects, between 1st March and 30th April 2020. Results: Thirty-one of 53 hospitals from 12 countries participated. Challenges reported included staff constraints (30% drop), reduction in planned monitoring activity (67% drop of site initiation visits and 64% of monitoring visits) and patient recruitment (61% drop compared with that in 2019). The percentage of phase I, phase II trials and molecular platforms closing to recruitment in at least one site was 48.5%, 61.3% and 64.3%, respectively. In addition, 26% of sites had restrictions on performing trial assessments because of local contingency plans. Almost half of the units suffered impact upon pending contracts. Most hospitals (65%) are planning on improving organisational and structural changes. Conclusion: The study reveals a profound disruption of paediatric cancer early-phase clinical research due to the COVID-19 pandemic across Europe. Reported difficulties affected both patient care and monitoring activity. Efforts should be made to reallocate resources to avoid lost opportunities for patients and to allow the continued advancement of oncology research. Identified adaptations to clinical trial procedures may be integrated to increase preparedness of clinical research to futures crises.
- Published
- 2020
9. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium
- Author
-
Rubio San Simón, A, André, N, Cefalo, M, Aerts, I, Castañeda, A, Benezech, S, Makin, G, van Eijkelenburg, N, Nysom, K, Marshall, L, Gambart, M, Hladun, R, Rossig, C, Bergamaschi, L, Fagioli, F, Carpenter, B, Ducassou, S, Owens, C, Øra, I, Ribelles, A, De Wilde, B, Guerra García, P, Strullu, M, Rizzari, C, Ek, T, Hettmer, S, Gerber, N, Rawlings, C, Diezi, M, Palmu, S, Ruggiero, A, Verdú, J, de Rojas, T, Vassal, G, Geoerger, B, Moreno, L, Bautista, F, Cefalo, MG, van Eijkelenburg N, Ribelles, AJ, Rubio San Simón, A, André, N, Cefalo, M, Aerts, I, Castañeda, A, Benezech, S, Makin, G, van Eijkelenburg, N, Nysom, K, Marshall, L, Gambart, M, Hladun, R, Rossig, C, Bergamaschi, L, Fagioli, F, Carpenter, B, Ducassou, S, Owens, C, Øra, I, Ribelles, A, De Wilde, B, Guerra García, P, Strullu, M, Rizzari, C, Ek, T, Hettmer, S, Gerber, N, Rawlings, C, Diezi, M, Palmu, S, Ruggiero, A, Verdú, J, de Rojas, T, Vassal, G, Geoerger, B, Moreno, L, Bautista, F, Cefalo, MG, van Eijkelenburg N, and Ribelles, AJ
- Abstract
Introduction: Data regarding real-world impact on cancer clinical research during COVID-19 are scarce. We analysed the impact of the COVID-19 pandemic on the conduct of paediatric cancer phase I–II trials in Europe through the experience of the Innovative Therapies for Children with Cancer (ITCC). Methods: A survey was sent to all ITCC-accredited early-phase clinical trial hospitals including questions about impact on staff activities, recruitment, patient care, supply of investigational products and legal aspects, between 1st March and 30th April 2020. Results: Thirty-one of 53 hospitals from 12 countries participated. Challenges reported included staff constraints (30% drop), reduction in planned monitoring activity (67% drop of site initiation visits and 64% of monitoring visits) and patient recruitment (61% drop compared with that in 2019). The percentage of phase I, phase II trials and molecular platforms closing to recruitment in at least one site was 48.5%, 61.3% and 64.3%, respectively. In addition, 26% of sites had restrictions on performing trial assessments because of local contingency plans. Almost half of the units suffered impact upon pending contracts. Most hospitals (65%) are planning on improving organisational and structural changes. Conclusion: The study reveals a profound disruption of paediatric cancer early-phase clinical research due to the COVID-19 pandemic across Europe. Reported difficulties affected both patient care and monitoring activity. Efforts should be made to reallocate resources to avoid lost opportunities for patients and to allow the continued advancement of oncology research. Identified adaptations to clinical trial procedures may be integrated to increase preparedness of clinical research to futures crises.
- Published
- 2020
10. Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors
- Author
-
Ferrari, A, Brecht, I, Gatta, G, Schneider, D, Orbach, D, Cecchetto, G, Godzinski, J, Reguerre, Y, Bien, E, Stachowicz-Stencel, T, Ost, M, Magni, C, Kearns, P, Vassal, G, Massimino, M, Biondi, A, Bisogno, G, Trama, A, Brecht, IB, Schneider, DT, Stachowicz-Stencel, Te, Ferrari, A, Brecht, I, Gatta, G, Schneider, D, Orbach, D, Cecchetto, G, Godzinski, J, Reguerre, Y, Bien, E, Stachowicz-Stencel, T, Ost, M, Magni, C, Kearns, P, Vassal, G, Massimino, M, Biondi, A, Bisogno, G, Trama, A, Brecht, IB, Schneider, DT, and Stachowicz-Stencel, Te
- Abstract
Although all tumours are rare in childhood, there are some particularly rare paediatric cancers which have not benefited from advances made by the international paediatric oncology network. To establish a shared definition and produce a list of these entities, the European Union Joint Action on Rare Cancers (JARC) promoted a consensus effort. The definition was based on the incidence rates estimated using the information network on rare cancers (RARECAREnet) database, pooling data from 94 population-based cancer registries and 27 countries. The RARECAREnet list of cancers was used to estimate the incidence rates. This list groups cancers by combining the International Classification of Diseases for Oncology, third edition, morphology and topography codes. According to the consensus, very rare paediatric cancers were identified as those with an annual incidence <2/1000000 and corresponded to 11% of all cancers in patients aged 0–14 years. Two subgroups were identified: tumour types typical of childhood (i.e. hepatoblastoma, pleuropulmonary blastoma, pancreatoblastoma) and those typical of adult age (i.e. carcinomas, melanoma). The threshold of 2/1000000 could also be adopted in populations aged 0–19 years: in this case, three tumour types had an incidence rate which was >2/1000000 (i.e. thyroid and testicular cancers and skin melanoma), but the consensus experts considered them as ‘very rare’ according to their clinical needs (e.g. shortage of knowledge and clinical expertise as the other rare paediatric cancers). The JARC consensus produced a definition and a list of very rare paediatric cancers which may represent a starting point for prioritising research on these tumours, based on data and patients’ clinical needs.
- Published
- 2019
11. The SIOPE strategic plan: A European cancer plan for children and adolescents
- Author
-
Vassal, G, Schrappe, M, Pritchard-Jones, K, Arnold, F, Basset, L, Biondi, A, Bode, G, Eggert, A, Hjorth, L, Kameric, L, Kameric, N, Karner, S, Kearns, P, Kienesberger, A, Kowalczyk, J, Lack, P, Perilongo, G, Sullivan, R, Tsirou, A, Essiaf, S, Ladenstein, R, Vassal G., Schrappe M., Pritchard-Jones K., Arnold F., Basset L., Biondi A., Bode G., Eggert A., Hjorth L., Kameric L., Kameric N., Karner S., Kearns P., Kienesberger A., Kowalczyk J., Lack P., Perilongo G., Sullivan R., Tsirou A., Essiaf S., Ladenstein R., Vassal, G, Schrappe, M, Pritchard-Jones, K, Arnold, F, Basset, L, Biondi, A, Bode, G, Eggert, A, Hjorth, L, Kameric, L, Kameric, N, Karner, S, Kearns, P, Kienesberger, A, Kowalczyk, J, Lack, P, Perilongo, G, Sullivan, R, Tsirou, A, Essiaf, S, Ladenstein, R, Vassal G., Schrappe M., Pritchard-Jones K., Arnold F., Basset L., Biondi A., Bode G., Eggert A., Hjorth L., Kameric L., Kameric N., Karner S., Kearns P., Kienesberger A., Kowalczyk J., Lack P., Perilongo G., Sullivan R., Tsirou A., Essiaf S., and Ladenstein R.
- Published
- 2016
12. Roles of Clinical Research Networks in Pediatric Drug Development
- Author
-
Turner, M.A., Attar, S., Wildt, S.N. de, Vassal, G., Mangiarini, L., Giaquinto, C., Turner, M.A., Attar, S., Wildt, S.N. de, Vassal, G., Mangiarini, L., and Giaquinto, C.
- Abstract
Item does not contain fulltext, The evaluation of drugs that are used in children has been neglected historically but is now well established as an essential part of clinical drug development. The increase in pediatric activity among industry, and other sectors, has highlighted the importance of joint working. All participants in pediatric drug development need to be aware of the "big picture." An increasingly important part of this big picture in pediatrics, as in other populations, is the design and conduct of clinical trials in networks. This narrative review provides an overview of the roles of clinical research networks in pediatric drug development. Networks take many forms as specialty networks and geographic networks but work toward common principles, including sharing resources between trials, and using experience with trial conduct to improve trial design. Networks develop standardized processes for trial conduct (including performance management) that increase the speed and predictability of trial conduct while reducing burdens on sites, sponsors, and intermediaries. Networks can provide validated, real-world information about natural history, participant distribution, and standards of care to inform planning of development programs, including extrapolation and clinical trial simulation. Networks can work across geographic and jurisdictional barriers to promote global interoperability of drug development. Networks support participant centrality. Networks offer an opportunity to develop relationships with investigators, sites, and methodological experts that span pre-competitive foundations for drug development and specific products. Sustainable networks benefit all stakeholders by providing a multifunctional platform that promotes the quality and timeliness of clinical drug development.
- Published
- 2017
13. Roles of Clinical Research Networks in Pediatric Drug Development
- Author
-
Turner, M.A., Attar, S., Wildt, S.N. de, Vassal, G., Mangiarini, L., Giaquinto, C., Turner, M.A., Attar, S., Wildt, S.N. de, Vassal, G., Mangiarini, L., and Giaquinto, C.
- Abstract
Item does not contain fulltext, The evaluation of drugs that are used in children has been neglected historically but is now well established as an essential part of clinical drug development. The increase in pediatric activity among industry, and other sectors, has highlighted the importance of joint working. All participants in pediatric drug development need to be aware of the "big picture." An increasingly important part of this big picture in pediatrics, as in other populations, is the design and conduct of clinical trials in networks. This narrative review provides an overview of the roles of clinical research networks in pediatric drug development. Networks take many forms as specialty networks and geographic networks but work toward common principles, including sharing resources between trials, and using experience with trial conduct to improve trial design. Networks develop standardized processes for trial conduct (including performance management) that increase the speed and predictability of trial conduct while reducing burdens on sites, sponsors, and intermediaries. Networks can provide validated, real-world information about natural history, participant distribution, and standards of care to inform planning of development programs, including extrapolation and clinical trial simulation. Networks can work across geographic and jurisdictional barriers to promote global interoperability of drug development. Networks support participant centrality. Networks offer an opportunity to develop relationships with investigators, sites, and methodological experts that span pre-competitive foundations for drug development and specific products. Sustainable networks benefit all stakeholders by providing a multifunctional platform that promotes the quality and timeliness of clinical drug development.
- Published
- 2017
14. The SIOPE strategic plan: A European cancer plan for children and adolescents
- Author
-
Universitat Politècnica de València. Departamento de Mecánica de los Medios Continuos y Teoría de Estructuras - Departament de Mecànica dels Medis Continus i Teoria d'Estructures, Vassal, G., Schrappe, M., Pritchard-Jones, K., Arnold, F., Basset-Salom, Luisa, Biondi, A., Bode, G., Eggert, A., Hjorth, L., Kameric, L., Kameric, N., Karner, S., Kearns, P., Kienesberger, A., Kowalczyk, J., Lack, P., Perilongo, G., Sullivan, R., Tsirou, A., Essiaf, S., Landenstein, R., Universitat Politècnica de València. Departamento de Mecánica de los Medios Continuos y Teoría de Estructuras - Departament de Mecànica dels Medis Continus i Teoria d'Estructures, Vassal, G., Schrappe, M., Pritchard-Jones, K., Arnold, F., Basset-Salom, Luisa, Biondi, A., Bode, G., Eggert, A., Hjorth, L., Kameric, L., Kameric, N., Karner, S., Kearns, P., Kienesberger, A., Kowalczyk, J., Lack, P., Perilongo, G., Sullivan, R., Tsirou, A., Essiaf, S., and Landenstein, R.
- Abstract
[EN] Within the European Network for Cancer research in Children and Adolescents (ENCCA), SIOPE and the European paediatric haematology-oncology community have established a long-term sustainable Strategic Plan to increase the cure rate and the quality of survivorship for children and young people with cancer over the next ten years. The ultimate goal is to increase the diseaseand late-effect- free survival after 10 years from the diagnosis, and beyond. As a result of several initiatives to involve all stakeholders and ensure that all their points of view would be taken into account in the document, this long-term sustainable Strategic Plan has achieved a broad consensus, and will serve as the "European Cancer Plan for Children and Adolescents".
- Published
- 2016
15. The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report
- Author
-
Kager, L., Whelan, J., Dirksen, U., Hassan, B., Anninga, J., Bennister, L., Bovee, J.V., Brennan, B., Broto, J.M., Brugieres, L., Cleton-Jansen, A.M., Copland, C., Dutour, A., Fagioli, F., Ferrari, S., Fiocco, M., Fleuren, E.D., Gaspar, N., Gelderblom, H., Gerrand, C., Gerss, J., Gonzato, O., Graaf, W.T.A. van der, Hecker-Nolting, S., Herrero-Martin, D., Klco-Brosius, S., Kovar, H., Ladenstein, R., Lancia, C., Ledeley, M.C., McCabe, M.G., Metzler, M., Myklebost, O., Nathrath, M., Picci, P., Potratz, J., Redini, F., Richter, G.H., Reinke, D., Rutkowski, P., Scotlandi, K., Strauss, S., Thomas, D, Tirado, O.M., Tirode, F., Vassal, G., Bielack, S.S., Kager, L., Whelan, J., Dirksen, U., Hassan, B., Anninga, J., Bennister, L., Bovee, J.V., Brennan, B., Broto, J.M., Brugieres, L., Cleton-Jansen, A.M., Copland, C., Dutour, A., Fagioli, F., Ferrari, S., Fiocco, M., Fleuren, E.D., Gaspar, N., Gelderblom, H., Gerrand, C., Gerss, J., Gonzato, O., Graaf, W.T.A. van der, Hecker-Nolting, S., Herrero-Martin, D., Klco-Brosius, S., Kovar, H., Ladenstein, R., Lancia, C., Ledeley, M.C., McCabe, M.G., Metzler, M., Myklebost, O., Nathrath, M., Picci, P., Potratz, J., Redini, F., Richter, G.H., Reinke, D., Rutkowski, P., Scotlandi, K., Strauss, S., Thomas, D, Tirado, O.M., Tirode, F., Vassal, G., and Bielack, S.S.
- Abstract
Contains fulltext : 167540.pdf (publisher's version ) (Open Access), This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations. The ultimate goal is to further improve therapy and outcome in patients with bone sarcomas.
- Published
- 2016
16. The SIOPE strategic plan: A European cancer plan for children and adolescents
- Author
-
Universitat Politècnica de València. Departamento de Mecánica de los Medios Continuos y Teoría de Estructuras - Departament de Mecànica dels Medis Continus i Teoria d'Estructures, Vassal, G., Schrappe, M., Pritchard-Jones, K., Arnold, F., Basset-Salom, Luisa, Biondi, A., Bode, G., Eggert, A., Hjorth, L., Kameric, L., Kameric, N., Karner, S., Kearns, P., Kienesberger, A., Kowalczyk, J., Lack, P., Perilongo, G., Sullivan, R., Tsirou, A., Essiaf, S., Landenstein, R., Universitat Politècnica de València. Departamento de Mecánica de los Medios Continuos y Teoría de Estructuras - Departament de Mecànica dels Medis Continus i Teoria d'Estructures, Vassal, G., Schrappe, M., Pritchard-Jones, K., Arnold, F., Basset-Salom, Luisa, Biondi, A., Bode, G., Eggert, A., Hjorth, L., Kameric, L., Kameric, N., Karner, S., Kearns, P., Kienesberger, A., Kowalczyk, J., Lack, P., Perilongo, G., Sullivan, R., Tsirou, A., Essiaf, S., and Landenstein, R.
- Abstract
[EN] Within the European Network for Cancer research in Children and Adolescents (ENCCA), SIOPE and the European paediatric haematology-oncology community have established a long-term sustainable Strategic Plan to increase the cure rate and the quality of survivorship for children and young people with cancer over the next ten years. The ultimate goal is to increase the diseaseand late-effect- free survival after 10 years from the diagnosis, and beyond. As a result of several initiatives to involve all stakeholders and ensure that all their points of view would be taken into account in the document, this long-term sustainable Strategic Plan has achieved a broad consensus, and will serve as the "European Cancer Plan for Children and Adolescents".
- Published
- 2016
17. The SIOPE strategic plan: A European cancer plan for children and adolescents
- Author
-
Universitat Politècnica de València. Departamento de Mecánica de los Medios Continuos y Teoría de Estructuras - Departament de Mecànica dels Medis Continus i Teoria d'Estructures, Vassal, G., Schrappe, M., Pritchard-Jones, K., Arnold, F., Basset-Salom, Luisa, Biondi, A., Bode, G., Eggert, A., Hjorth, L., Kameric, L., Kameric, N., Karner, S., Kearns, P., Kienesberger, A., Kowalczyk, J., Lack, P., Perilongo, G., Sullivan, R., Tsirou, A., Essiaf, S., Landenstein, R., Universitat Politècnica de València. Departamento de Mecánica de los Medios Continuos y Teoría de Estructuras - Departament de Mecànica dels Medis Continus i Teoria d'Estructures, Vassal, G., Schrappe, M., Pritchard-Jones, K., Arnold, F., Basset-Salom, Luisa, Biondi, A., Bode, G., Eggert, A., Hjorth, L., Kameric, L., Kameric, N., Karner, S., Kearns, P., Kienesberger, A., Kowalczyk, J., Lack, P., Perilongo, G., Sullivan, R., Tsirou, A., Essiaf, S., and Landenstein, R.
- Abstract
[EN] Within the European Network for Cancer research in Children and Adolescents (ENCCA), SIOPE and the European paediatric haematology-oncology community have established a long-term sustainable Strategic Plan to increase the cure rate and the quality of survivorship for children and young people with cancer over the next ten years. The ultimate goal is to increase the diseaseand late-effect- free survival after 10 years from the diagnosis, and beyond. As a result of several initiatives to involve all stakeholders and ensure that all their points of view would be taken into account in the document, this long-term sustainable Strategic Plan has achieved a broad consensus, and will serve as the "European Cancer Plan for Children and Adolescents".
- Published
- 2016
18. The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report
- Author
-
Kager, L., Whelan, J., Dirksen, U., Hassan, B., Anninga, J., Bennister, L., Bovee, J.V., Brennan, B., Broto, J.M., Brugieres, L., Cleton-Jansen, A.M., Copland, C., Dutour, A., Fagioli, F., Ferrari, S., Fiocco, M., Fleuren, E.D., Gaspar, N., Gelderblom, H., Gerrand, C., Gerss, J., Gonzato, O., Graaf, W.T.A. van der, Hecker-Nolting, S., Herrero-Martin, D., Klco-Brosius, S., Kovar, H., Ladenstein, R., Lancia, C., Ledeley, M.C., McCabe, M.G., Metzler, M., Myklebost, O., Nathrath, M., Picci, P., Potratz, J., Redini, F., Richter, G.H., Reinke, D., Rutkowski, P., Scotlandi, K., Strauss, S., Thomas, D, Tirado, O.M., Tirode, F., Vassal, G., Bielack, S.S., Kager, L., Whelan, J., Dirksen, U., Hassan, B., Anninga, J., Bennister, L., Bovee, J.V., Brennan, B., Broto, J.M., Brugieres, L., Cleton-Jansen, A.M., Copland, C., Dutour, A., Fagioli, F., Ferrari, S., Fiocco, M., Fleuren, E.D., Gaspar, N., Gelderblom, H., Gerrand, C., Gerss, J., Gonzato, O., Graaf, W.T.A. van der, Hecker-Nolting, S., Herrero-Martin, D., Klco-Brosius, S., Kovar, H., Ladenstein, R., Lancia, C., Ledeley, M.C., McCabe, M.G., Metzler, M., Myklebost, O., Nathrath, M., Picci, P., Potratz, J., Redini, F., Richter, G.H., Reinke, D., Rutkowski, P., Scotlandi, K., Strauss, S., Thomas, D, Tirado, O.M., Tirode, F., Vassal, G., and Bielack, S.S.
- Abstract
Contains fulltext : 167540.pdf (publisher's version ) (Open Access), This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations. The ultimate goal is to further improve therapy and outcome in patients with bone sarcomas.
- Published
- 2016
19. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review
- Author
-
Andritsch, E, Beishon, M, Bielack, S, Bonvalot, S, Casali, P, Crul, M, Delgado-Bolton, R, Donati, D, Douis, H, Haas, R, Hogendoorn, P, Kozhaeva, O, Lavender, V, Lovely, J, Negrouk, A, Pereira, P, Roca, P, Rochette de Lempdes, G, Saarto, T, van Berck, B, Vassal, G, Wartenberg, M, Yared, W, Costa, A, Naredi, P, Andritsch, E, Beishon, M, Bielack, S, Bonvalot, S, Casali, P, Crul, M, Delgado-Bolton, R, Donati, D, Douis, H, Haas, R, Hogendoorn, P, Kozhaeva, O, Lavender, V, Lovely, J, Negrouk, A, Pereira, P, Roca, P, Rochette de Lempdes, G, Saarto, T, van Berck, B, Vassal, G, Wartenberg, M, Yared, W, Costa, A, and Naredi, P
- Abstract
ECCO essential requirements for quality cancer care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to patients who have a specific tumour type. They are written by European experts representing all disciplines involved in cancer care. ERQCC papers give oncology teams, patients, policymakers and managers an overview of the elements needed in any healthcare system to provide high quality of care throughout the patient journey. References are made to clinical guidelines and other resources where appropriate, and the focus is on care in Europe. Sarcoma: essential requirements for quality care • Sarcomas – which can be classified into soft tissue and bone sarcomas – are rare, but all rare cancers make up more than 20% of cancers in Europe, and there are substantial inequalities in access to high-quality care. Sarcomas, of which there are many subtypes, comprise a particularly complex and demanding challenge for healthcare systems and providers. This paper presents essential requirements for quality cancer care of soft tissue sarcomas in adults and bone sarcomas. • High-quality care must only be carried out in specialised sarcoma centres (including paediatric cancer centres) which have both a core multidisciplinary team and an extended team of allied professionals, and which are subject to quality and audit procedures. Access to such units is far from universal in all European countries. • It is essential that, to meet European aspirations for high-quality comprehensive cancer control, healthcare organisations implement the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis and follow-up, to treatment, to improve survival and quality of life for patients. Conclusion Taken together, the information presented in this paper provides a comprehensive description of the essential requirements for establishing a high-quality service for soft t
- Published
- 2016
20. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper
- Author
-
Casali, P.G. (Paolo), Bruzzi, P. (P.), Bogaerts, J. (Jan), Blay, J.Y. (Jean Yves), Aapro, M. (Matti), Adamous, A., Berruti, A. (Alfredo), Bressington, J., Bruzzi, B., Capocaccia, R. (Riccardo), Cardoso, F. (Fatima), Celis, J.E., Cervantes, A. (Andres), Ciardiello, F., Claussen, C., Coleman, M., Comis, S., Craine, S., De Boltz, D., De Lorenzo, F., Dei Tos, A.P. (Angelo), Gatta, G. (Gemma), Geissler, J. (Jan), Giuliani, R., Grande, E. (Enrico), Gronchi, A. (Alessandro), Jezdic, S., Jonsson, B., Jost, L., Keulen, H., Lacombe, D. (Denis), Lamory, G., Le Cam, Y., Leto di Priolo, S., Licitra, L., Macchia, F., Margulies, A., Marreaud, S. (Sandrine), McVie, G., Narbutas, S., Oliver, K., Pavlidis, N., Pelouchova, J., Pentheroudakis, G., Piccart, M.J. (Martine), Pierotti, M. (Marco Alessandro), Pravettoni, G., Redmond, K., Riegman, P.H.J. (Peter), Ruffilli, M.P., Ryner, D., Sandrucci, S., Seymour, M., Torri, V. (Valter), Trama, A., Belle, S. (S.) van, Vassal, G., Wartenberg, M., Watts, C., Wilson, A., Yared, W., Casali, P.G. (Paolo), Bruzzi, P. (P.), Bogaerts, J. (Jan), Blay, J.Y. (Jean Yves), Aapro, M. (Matti), Adamous, A., Berruti, A. (Alfredo), Bressington, J., Bruzzi, B., Capocaccia, R. (Riccardo), Cardoso, F. (Fatima), Celis, J.E., Cervantes, A. (Andres), Ciardiello, F., Claussen, C., Coleman, M., Comis, S., Craine, S., De Boltz, D., De Lorenzo, F., Dei Tos, A.P. (Angelo), Gatta, G. (Gemma), Geissler, J. (Jan), Giuliani, R., Grande, E. (Enrico), Gronchi, A. (Alessandro), Jezdic, S., Jonsson, B., Jost, L., Keulen, H., Lacombe, D. (Denis), Lamory, G., Le Cam, Y., Leto di Priolo, S., Licitra, L., Macchia, F., Margulies, A., Marreaud, S. (Sandrine), McVie, G., Narbutas, S., Oliver, K., Pavlidis, N., Pelouchova, J., Pentheroudakis, G., Piccart, M.J. (Martine), Pierotti, M. (Marco Alessandro), Pravettoni, G., Redmond, K., Riegman, P.H.J. (Peter), Ruffilli, M.P., Ryner, D., Sandrucci, S., Seymour, M., Torri, V. (Valter), Trama, A., Belle, S. (S.) van, Vassal, G., Wartenberg, M., Watts, C., Wilson, A., and Yared, W.
- Abstract
While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in clinical studies on rare cancers, as well as adaptive trials in general, with their inherent potential of flexibility when properly applied. While clinical studies are the mainstay to test hypotheses, the potential of electronic patient records should be exploited to generate new hypotheses, to create external controls for future studies (when internal controls are unpractical), to study effectiveness of new treatments in real conditions. Framework study protocols in specific rare cancers to stepwisely test sets of new agents, as from the early post-phase I dev
- Published
- 2015
- Full Text
- View/download PDF
21. Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda
- Author
-
Vassal, G, Fitzgerald, E, Schrappe, M, Arnold, F, Kowalczyk, J, Walker, D, Hjorth, L, Riccardi, R, Kienesberger, A, Jones, K, Valsecchi, M, Janic, D, Hasle, H, Kearns, P, Petrarulo, G, Florindi, F, Essiaf, S, Ladenstein, R, Ladenstein, R., VALSECCHI, MARIA GRAZIA, Vassal, G, Fitzgerald, E, Schrappe, M, Arnold, F, Kowalczyk, J, Walker, D, Hjorth, L, Riccardi, R, Kienesberger, A, Jones, K, Valsecchi, M, Janic, D, Hasle, H, Kearns, P, Petrarulo, G, Florindi, F, Essiaf, S, Ladenstein, R, Ladenstein, R., and VALSECCHI, MARIA GRAZIA
- Abstract
In Europe, 6,000 young people die of cancer yearly, the commonest disease causing death beyond the age of 1 year. In addition, 300,000-500,000 European citizens are survivors of a childhood cancer and up to 30% of them have severe long-term sequelae of their treatment. Increasing both cure and quality of cure are the two goals of the European paediatric haematology/oncology community. SIOPE coordinates and facilitates research, care and training which are implemented by the 18 European study groups and 23 national paediatric haematology/oncology societies. SIOPE is the European branch of the International Society of Paediatric Oncology and one of the six founding members of the European Cancer Organisation. SIOPE is preparing its strategic agenda to assure long-term sustainability of clinical and translational research in paediatric malignancies over the next 15 years. SIOPE tackles the issues of equal access to standard care and research across Europe and improvement of long term follow up. SIOPE defined a comprehensive syllabus for training European specialists. A strong partnership with parent, patient and survivor organisations is being developed to successfully achieve the goals of this patient-centred agenda. SIOPE is advocating in the field of EU policies, such as the Clinical Trials Regulation and the Paediatric Medicine Regulation, to warrant that the voice of young people is heard and their needs adequately addressed. SIOPE and the European community are entirely committed to the global agenda against childhood cancers to overcome the challenges to increasing both cure and quality of cure of young people with cancer.
- Published
- 2014
22. Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda
- Author
-
Vassal, G, Fitzgerald, E, Schrappe, M, Arnold, F, Kowalczyk, J, Walker, D, Hjorth, L, Riccardi, Riccardo, Kienesberger, A, Jones, K, Valsecchi, Mg, Janic, D, Hasle, H, Kearns, P, Petrarulo, G, Florindi, F, Essiaf, S, Ladenstein, R., Riccardi, Riccardo (ORCID:0000-0001-7515-6622), Vassal, G, Fitzgerald, E, Schrappe, M, Arnold, F, Kowalczyk, J, Walker, D, Hjorth, L, Riccardi, Riccardo, Kienesberger, A, Jones, K, Valsecchi, Mg, Janic, D, Hasle, H, Kearns, P, Petrarulo, G, Florindi, F, Essiaf, S, Ladenstein, R., and Riccardi, Riccardo (ORCID:0000-0001-7515-6622)
- Abstract
In Europe, 6,000 young people die of cancer yearly, the commonest disease causing death beyond the age of 1 year. In addition, 300,000-500,000 European citizens are survivors of a childhood cancer and up to 30% of them have severe long-term sequelae of their treatment. Increasing both cure and quality of cure are the two goals of the European paediatric haematology/oncology community. SIOPE coordinates and facilitates research, care and training which are implemented by the 18 European study groups and 23 national paediatric haematology/oncology societies. SIOPE is the European branch of the International Society of Paediatric Oncology and one of the six founding members of the European Cancer Organisation. SIOPE is preparing its strategic agenda to assure long-term sustainability of clinical and translational research in paediatric malignancies over the next 15 years. SIOPE tackles the issues of equal access to standard care and research across Europe and improvement of long term follow up. SIOPE defined a comprehensive syllabus for training European specialists. A strong partnership with parent, patient and survivor organisations is being developed to successfully achieve the goals of this patient-centred agenda. SIOPE is advocating in the field of EU policies, such as the Clinical Trials Regulation and the Paediatric Medicine Regulation, to warrant that the voice of young people is heard and their needs adequately addressed. SIOPE and the European community are entirely committed to the global agenda against childhood cancers to overcome the challenges to increasing both cure and quality of cure of young people with cancer.
- Published
- 2014
23. New policies to address the global burden of childhood cancers
- Author
-
Sullivan, R, Kowalczyk, J, Agarwal, B, Ladenstein, R, Fitzgerald, E, Barr, R, Steliarova Foucher, E, Magrath, I, Howard, S, Kruger, M, Valsecchi, M, Biondi, A, Grundy, P, Smith, M, Adamson, P, Vassal, G, Pritchard Jones, K, Kowalczyk, JR, Howard, SC, Smith, MA, Pritchard Jones, K., VALSECCHI, MARIA GRAZIA, BIONDI, ANDREA, Sullivan, R, Kowalczyk, J, Agarwal, B, Ladenstein, R, Fitzgerald, E, Barr, R, Steliarova Foucher, E, Magrath, I, Howard, S, Kruger, M, Valsecchi, M, Biondi, A, Grundy, P, Smith, M, Adamson, P, Vassal, G, Pritchard Jones, K, Kowalczyk, JR, Howard, SC, Smith, MA, Pritchard Jones, K., VALSECCHI, MARIA GRAZIA, and BIONDI, ANDREA
- Abstract
Childhood cancer is a major global health issue. Every year, almost 100 000 children die from cancer before the age of 15 years, more than 90% of them in resource-limited countries. Here, we review the key policy issues for the delivery of better care, research, and education of professionals and patients. We present a key list of time-limited proposals focusing on change to health systems and research and development. These include sector and system reforms to make care affordable to all, policies to promote growth of civil society around both cancer and Millennium Development Goals, major improvements to public health services (particularly the introduction of national cancer plans), improved career development, and increased remuneration of specialist health-care workers and government support for childhood cancer registries. Research and development proposals focus on sustainable funding, the establishment of more research networks, and clinical research specifically targeted at the needs of low-income and middle-income countries. Finally, we present proposals to address the need for clinical trial innovation, the complex dichotomy of regulations, and the threats to the availability of data for childhood cancers. © 2013 Elsevier Ltd.
- Published
- 2013
24. The state of research into children with cancer across Europe : new policies for a new decade
- Author
-
Pritchard-Jones, K, Lewison, G, Camporesi, S, Vassal, G, Ladenstein, R, Benoit, Y, Predojevic, Js, Sterba, J, Stary, J, Eckschlager, T, Schroeder, H, Doz, F, Creutzig, U, Klingebiel, T, Kosmidis, Hv, Garami, M, Pieters, R, O'Meara, A, Dini, G, Riccardi, R, Rascon, J, Rageliene, L, Calvagna, V, Czauderna, P, Kowalczyk, Jr, Gil-da-Costa, Mj, Norton, L, Pereira, F, Janic, D, Puskacova, J, Jazbec, J, Canete, A, Hjorth, L, Ljungman, Gustaf, Kutluk, T, Morland, B, Stevens, M, Walker, D, Sullivan, R, Pritchard-Jones, K, Lewison, G, Camporesi, S, Vassal, G, Ladenstein, R, Benoit, Y, Predojevic, Js, Sterba, J, Stary, J, Eckschlager, T, Schroeder, H, Doz, F, Creutzig, U, Klingebiel, T, Kosmidis, Hv, Garami, M, Pieters, R, O'Meara, A, Dini, G, Riccardi, R, Rascon, J, Rageliene, L, Calvagna, V, Czauderna, P, Kowalczyk, Jr, Gil-da-Costa, Mj, Norton, L, Pereira, F, Janic, D, Puskacova, J, Jazbec, J, Canete, A, Hjorth, L, Ljungman, Gustaf, Kutluk, T, Morland, B, Stevens, M, Walker, D, and Sullivan, R
- Abstract
Overcoming childhood cancers is critically dependent on the state of research. Understanding how, with whom and what the research community is doing with childhood cancers is essential for ensuring the evidence-based policies at national and European level to support children, their families and researchers. As part of the European Union funded EUROCANCERCOMS project to study and integrate cancer communications across Europe, we have carried out new research into the state of research in childhood cancers. We are very grateful for all the support we have received from colleagues in the European paediatric oncology community, and in particular from Edel Fitzgerald and Samira Essiaf from the SIOP Europe office. This report and the evidence-based policies that arise from it come at a important junction for Europe and its Member States. They provide a timely reminder that research into childhood cancers is critical and needs sustainable long-term support.
- Published
- 2011
- Full Text
- View/download PDF
25. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.
- Author
-
Geoerger, B, Chisholm, J, Le Deley, Mc, Gentet, Jc, Zwaan, Cm, Dias, N, Jaspan, T, Hugh, K, Couanet, D, Hain, S, Devos, A, Riccardi, Riccardo, Cesare, C, Boos, J, Frappaz, D, Leblond, P, Aerts, I, Vassal, G., Riccardi, Riccardo (ORCID:0000-0001-7515-6622), Geoerger, B, Chisholm, J, Le Deley, Mc, Gentet, Jc, Zwaan, Cm, Dias, N, Jaspan, T, Hugh, K, Couanet, D, Hain, S, Devos, A, Riccardi, Riccardo, Cesare, C, Boos, J, Frappaz, D, Leblond, P, Aerts, I, Vassal, G., and Riccardi, Riccardo (ORCID:0000-0001-7515-6622)
- Abstract
AIM: To assess objective response rates after 4 cycles of gemcitabine in combination with oxaliplatin in children and adolescents with relapsed or refractory solid tumours. METHODS: This multicentre, non-randomised Phase II study included five strata: neuroblastoma, osteosarcoma, medulloblastoma and other CNS tumours strata with two-stage Simon designs and a miscellaneous, extra-cranial solid tumour stratum with descriptive design. Eligibility criteria included: age 6 months to 21 years; measurable, relapsed or refractory solid malignancy; no more than one previous salvage therapy. Gemcitabine was administered intravenously at 1000 mg/m(2) over 100 min followed by oxaliplatin at 100mg/m(2) over 120 min on Day 1 of a 14-d cycle. Tumour response was assessed every 4 cycles according to WHO criteria. RESULTS: Ninety-three out of 95 patients enrolled in 25 centres received treatment: 12 neuroblastoma; 12 osteosarcoma; 14 medulloblastoma; 13 other CNS tumours and 42 miscellaneous non-CNS solid tumours. Median age was 11.7 years (range, 1.3-20.8 years). Tumour control (CR+PR+SD) at 4 cycles was obtained in 30/93 evaluable patients (32.3%; 95% confidence interval (CI), 22.9-42.7%), including four PR: 1/12 patients with osteosarcoma, 1/12 with medulloblastoma, 1/12 with rhabdomyosarcoma and 1/4 with other sarcoma. Five out of 12 eligible patients with neuroblastoma experienced stable disease. During a total of 481 treatment cycles (median 4, range 1-24 per patient), the most common treatment-related toxicities were haematologic (leukopenia, neutropenia, thrombocytopenia) and neurological (dysesthesia, paresthesia). CONCLUDING STATEMENT: The gemcitabine-oxaliplatin combination administered in a bi-weekly schedule has acceptable safety profile with limited activity in children with relapsed or refractory solid tumours.
- Published
- 2011
26. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
- Author
-
Geoerger, B, Hargrave, D, Thomas, F, Ndiaye, A, Frappaz, D, Andreiuolo, F, Varlet, P, Aerts, I, Riccardi, Riccardo, Jaspan, T, Chatelut, E, Le Deley, Mc, Paoletti, X, Saint Rose, C, Leblond, P, Morland, B, Gentet, Jc, Meresse, V, Vassal, G., Riccardi, Riccardo (ORCID:0000-0001-7515-6622), Geoerger, B, Hargrave, D, Thomas, F, Ndiaye, A, Frappaz, D, Andreiuolo, F, Varlet, P, Aerts, I, Riccardi, Riccardo, Jaspan, T, Chatelut, E, Le Deley, Mc, Paoletti, X, Saint Rose, C, Leblond, P, Morland, B, Gentet, Jc, Meresse, V, Vassal, G., and Riccardi, Riccardo (ORCID:0000-0001-7515-6622)
- Abstract
This multicenter phase I study aimed to establish the recommended dose (RD) of the epidermal growth factor receptor (EGFR) inhibitor erlotinib, given as monotherapy or with radiotherapy to children with malignant brain tumors. Group 1 included patients with refractory or relapsing brain tumors receiving erlotinib alone, and group 2 included newly diagnosed patients with brainstem gliomas receiving radiotherapy and erlotinib. A conventional 3 + 3 dose escalation and a continual reassessment method, respectively, were utilized in 4 dose levels: 75, 100, 125, and 150 mg/m2 per day. Fifty-one children were enrolled (30 and 21, respectively); 50 received treatment. The RD of erlotinib was 125 mg/m2 per day as monotherapy or in combination with radiotherapy. Overall, 230 adverse events in 44 patients were possibly treatment related (216, grades 1 and 2; 9, grade 3; 1, grade 4; 4, grade 5). Dermatologic and neurologic symptoms were common; intratumoral hemorrhage was confirmed in 3 patients. In group 1, 8 of 29 patients (28%) had stable disease with tumor regression approaching 50% in a malignant glioma and an anaplastic oligoastrocytoma. In group 2, overall survival was 12.0 months. EGFR overexpression by immunohistochemistry was found in 17 of 38 (45%) tumor samples analyzed, with a partial gain of 7p11.2 in 1 glioblastoma; phosphate and tensin homolog loss was frequent in brainstem glioma (15 of 19). Mean (95% CI) apparent clearance and volume of distribution for erlotinib were 4.0 L/h (3.4-4.5 L/h) and 98.6 L (69.8-127.0 L), respectively, and were independent of the dose level; mean half-life was 16.6 hours. Thus, erlotinib 125 mg/m2 per day has an acceptable tolerability profile in pediatric patients with brain tumors and can be combined with radiotherapy
- Published
- 2011
27. The role of the Innovative Therapies for Children with Cancer' (ITCC) European consortium
- Author
-
Zwaan, Cm, Kearns, P, Caron, H, Verschuur, A, Riccardi, Riccardo, Boos, J, Doz, F, Geoerger, B, Morland, B, Vassal, G., Riccardi, Riccardo (ORCID:0000-0001-7515-6622), Zwaan, Cm, Kearns, P, Caron, H, Verschuur, A, Riccardi, Riccardo, Boos, J, Doz, F, Geoerger, B, Morland, B, Vassal, G., and Riccardi, Riccardo (ORCID:0000-0001-7515-6622)
- Abstract
Overall survival from childhood malignancies has dramatically improved, with survival rates now reaching over 70%. Nevertheless, some types of childhood cancer remain a difficult challenge, and for those who survive the burden of treatment can be considerable. The current paradigm for new cancer therapies is to increase our knowledge of the molecular basis of carcinogenesis, followed by the development of cancer-cell specific therapies. Historically, drug development was focused on adult cancers, and the potential efficacy in childhood malignancies was not considered. Recently, a European academic consortium was established, namely 'innovative therapies for children with cancer' (ITCC), to address this unmet need. This initiative is focused on the evaluation of novel agents in pediatric cancer pre-clinical models, and early clinical development of promising new drugs. The number of pediatric patients eligible to participate in such trials is limited, and accurate pre-clinical evaluation may provide evidence-based prioritization for clinical development. Until recently, clinical development of new drugs in childhood cancer was restricted by the limited accessibility of such agents. Recent changes in EU legislation oblige pharmaceutical companies to provide pediatric clinical data for all new drugs relevant to children, including anti-cancer drugs. Pediatric consortiums like ITCC have established networks of expertise with the specific aim of evaluating new drugs for the treatment of childhood cancers. Through proper evaluation in collaborative clinical trials we will learn how best to use these new therapeutic approaches and improve the survival rates and reduce toxicity for children with cancer.
- Published
- 2010
28. Conduct of phase I trials in children with cancer
- Author
-
Smith, M, Bernstein, M, Bleyer, Wa, Borsi, Jd, Ho, P, Lewis, Ij, Pearson, A, Pein, F, Pratt, C, Reaman, G, Riccardi, Riccardo, Seibel, N, Trueworthy, R, Ungerleider, R, Vassal, G, Vietti, T., Riccardi, Riccardo (ORCID:0000-0001-7515-6622), Smith, M, Bernstein, M, Bleyer, Wa, Borsi, Jd, Ho, P, Lewis, Ij, Pearson, A, Pein, F, Pratt, C, Reaman, G, Riccardi, Riccardo, Seibel, N, Trueworthy, R, Ungerleider, R, Vassal, G, Vietti, T., and Riccardi, Riccardo (ORCID:0000-0001-7515-6622)
- Abstract
PURPOSE AND METHODS: Future progress in the care of children with cancer requires appropriate evaluations of promising new agents for pediatric indications, beginning with well-conducted phase I trials. This report summarizes current guidelines for the conduct of pediatric phase I trials and represents a consensus between American and European investigators. The primary objective of pediatric phase I trials is to define safe and appropriate doses and schedules of new agents that can subsequently be used in phase II trials to test for activity against specific childhood malignancies. Prioritization of agents for evaluation in children is critical, since many more investigational agents are evaluated in adult patients than can be systematically evaluated in children. Considerations used in prioritizing agents include activity in xenograft models, novel mechanism of action, favorable drug-resistance profile, and activity observed in adult trials of the agent. RESULTS AND CONCLUSION: Distinctive characteristics of pediatric phase I trials, in comparison to adult phase I trials, include the necessity for multiinstitutional participation and their higher starting dose (typically 80% of the adult maximum-tolerated dose [MTD]), both of which reflect the relative unavailability of appropriate patients. The application of uniform eligibility criteria and standard definitions for MTD and dose-limiting toxicity (DLT) help to assure that pediatric phase I trials are safely conducted and reliably identify appropriate doses and schedules of agents for phase II evaluation. Where possible, pediatric phase I trials also define the pharmacokinetic behavior of new agents in children.
- Published
- 1998
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.